Transpl Infect Dis. 2021 Sep 10. doi: 10.1111/tid.13729. Online ahead of print.
ABSTRACT
BACKGROUND: The management of active tuberculosis (TB) in solid organ transplantation (SOT) recipients is challenging given the pharmacological interaction and the potential delays in diagnosis due to atypical presentation. The incidence rates (IRs) of post-SOT TB from whole recipients’ cohort in high-endemic country have not been evaluated.
METHODS: We established SOT cohort (n = 15,598) and confirmed cases of TB between 2011 and 2015 from the Korean National Health Insurance Database using ICD-10 codes. After excluding 1,302 and 180 SOT-recipients due to age (< 18 years) and presence of pre-SOT TB and/or treatment for latent TB during wash-out period between 2006 and cohort entry, we analyzed 14,116 SOT recipients and 70,580 individuals with no history of SOT matched by age and sex. The hazard ratios (HRs) of IRs were adjusted for age, sex, low-income status, diabetes mellitus, chronic co-morbidities, and anti-TNF-α therapy.
RESULTS: The IR of TB was significantly higher (adjusted HR [aHR]: 6.1, 95% confidence interval [CI]: 4.5-7.6) in SOT recipients (4.9/1,000 person-years) than in non-SOT individuals (0.8/1,000 person-years). Of the transplanted organs, pancreas (pancreas alone and simultaneous pancreas-kidney) and lung had the highest IR (aHR: 16.3 [6.1-42.2] and 16.1 [5.9-43.8], respectively). The use of anti-thymocyte globulin and azathioprine was associated with a higher IR (aHR: 1.53 [1.01-2.43] and 3.92 [1.21-12.47], respectively), but basiliximab was associated with a lower IR (aHR: 0.67 [0.48-0.98]).
CONCLUSION: The IR of TB in SOT recipients, especially in pancreas and lung, was significantly higher than that in non-SOT population. This article is protected by copyright. All rights reserved.
PMID:34505751 | DOI:10.1111/tid.13729
